Effect of the Pediatric Exclusivity Provision on children's access to medicines

British Journal of Clinical Pharmacology

Volumn 59, Issue 6, 2005, Pages 730-735

  Grieve, Joanne ^a   Tordoff, June ^a   Reith, David ^b,c   Norris, Pauline ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c DUNEDIN HOSPITAL   (New Zealand)

Author keywords

Child; Off label; Pediatric Exclusivity; Registration; Unlicensed

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIPARASITIC AGENT; CARDIOVASCULAR AGENT; DERMATOLOGICAL AGENT; GASTROINTESTINAL AGENT; IMMUNOMODULATING AGENT; INSECT REPELLENT; INSECTICIDE; RESPIRATORY TRACT AGENT; SEX HORMONE; URINARY TRACT AGENT;

ADOLESCENT; ARTICLE; AUSTRALIA; CONSULTATION; DRUG UTILIZATION; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ACCESS; HUMAN; INFANT; LICENSING; NEW ZEALAND; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; UNITED KINGDOM; UNITED STATES;

AGE FACTORS; AUSTRALIA; CHILD; CHILD, PRESCHOOL; DRUG APPROVAL; GREAT BRITAIN; HUMANS; INFANT; INFANT, NEWBORN; LEGISLATION, DRUG; LICENSURE; NEW ZEALAND; PEDIATRICS; PHARMACEUTICAL PREPARATIONS; UNITED STATES;

EID: 20644445855     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02327.x     Document Type: Article

References (28)

1. Conroy S. Unlicensed and off-label drug use: issues and recommendations. Paediatr Drugs 2002; 4: 353-9.
2. Shirkey HC. Editorial comment: Therapeutic orphans. J Pediatr 1968; 72: 119-20.
3. Nahata MC. Licensing of medicines for children in the USA. Paediatric Perinatal Drug Ther 1997; 1: 50-1.
4. Turner S, Nunn AJ, Choonara I. Unlicensed drug use in children in the UK. Paediatric Perinatal Drug Ther 1997; 1: 52-5.
5. Chui J, Tordoff J, Kennedy J, Reith D. Trends in accessibility to medicines for children in New Zealand: 1998-2002. Br J Clin Pharmacol 2004; 57: 322-7.
6. Chui J, Tordoff J, Reith D. Changes in availability of Paediatric Medicines in Australia between 1998 and 2002. Br J Clin Pharmacol in press.
7. Impicciatore P, Choonara I. Status of new medicines approved by the European Medicines Evaluation Agency regarding paediatric use. Br J Clin Pharmacol 1999; 48: 15-8.
8. US Food and Drug Administration Centre for Drug Evaluation and Research. Food and Drug Administration Modernisation Act of 1997 - Section III: Pediatric Studies of Drugs. http://www.fda.gov/ cder/guidance/105-115.htm 1997; Accessed 5 March 2004
9. US Food and Drug Administration. Best Pharmaceuticals for Children Act. http://www.fda.gov/opacom/laws/pharmkids/ contents.html 2002; Accessed 21 January 2004.
10. Holdsworth MT. Pediatric drug research - the road less traveled. The Ann Pharmacotherapy 2003; 37: 586-91.
11. US Food and Drug Administration. Update of list of approved drugs for which additional pediatric information may produce health benefits in the pediatric population. http://www.fda.gov/ cder/pediatric/peddrugsfinal.htm; Accessed 10 November 2003.
12. US Food and Drug Administration. The Pediatric Exclusivity Provision - January 2001; Status Report to Congress. http:// www.fda.gov/cder/pediatric/ reportcong01.pdf 2001; Accessed 22 January 2004: 4-7.
13. US Food and Drug Administration. Approved active moieties to which FDA has granted Pediatric Exclusivity for Pediatric Studies under Section 505A of the Federal Food, Drug and Cosmetic Act. http://www.fda.gov/cder/pediatric/ exgrant.htm. Accessed: 10 November 2003.
14. Sutcliffe AG. Prescribing medicines for children. BMJ 1999; 319: 70-1.
15. Bralow L. Physicians Desk Reference 2004, Montvale, NJ: Thomson PDR, 2004.
16. GlaxoSmithKline. Prescription medicines. http://www.gsk.com/ products/prescriptionmedicines.shtml 2003; Accessed 23 January 2004.
17. Merck. Merck website. http://www.merck.com 2004; Accessed 23 January 2004.
18. Bristol-MyersSquibb. Products. http://www.bms.com/products/ data/ 2004; Accessed 23 January 2004.
19. Roche. Roche website. http://www.rocheusa.com 2004; Accessed 23 January 2004.
20. Forest Pharmaceuticals. Celexa citalopram HBr. http:// www.celexa.com 2004; Accessed 23 January 2004.
21. Datapharm Communications Ltd. Electronic Medicines Compendium. http://emc.medicines.org.uk 2003; Accessed 26 January 2004.
22. Ministry of Health. New Zealand Medicines and Medical Devices Safety Authority. http://www.medsafe.govt.New Zealand. Accessed 21 January 2004.
23. Thomas J. Australian Prescription Products Guide 1998: Australian Pharmaceutical Publishing Co. Limited, Hawthorn, Victoria; 1998.
24. Anonymous. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Clinical Investigation of Medicinal Products in the Pediatric Population. http://www.fda.gov/cder/guidance/ 4099FNL.pdf 2000; Accessed 26 January 2004: 9.
25. WHO Collaborating Centre for Drug Statistics Methodology. ATC/ DDD Index 2004. http://www.whocc.no/atcddd/indexdatabase 2004; Accessed 26 January 2004.
26. STATA. Intercooled STATA 8.0 for Windows. College Station, TX: Stata Corporation; 2003.
27. US Food and Drug Administration Center for Drug Evaluation and Research. Paediatric Exclusivity Labeling Changes as of February 6, 2004. http://www.fda.gov/cder/pediatric/labelchange.htm. Accessed 4 April 2004.
28. Waechter F. Paroxetine must not be given to patients under 18. BMJ 2003; 326 (7402): 1282.